More research is needed to find the optimal dose of anti-flu drug Tamiflu for use in the event of a possible pandemic triggered by bird flu, a U.S. expert on the disease said on Wednesday.Dr John Beigel of the National Institutes of Health said Roche Holding AG’s medicine remained the best available treatment but doctors needed better evidence-based guidance on its use."Good rigorous data is lacking,” Beigel told a bird flu conference organised by investment bank UBS.Beigel said he was currently working with Roche to develop a new clinical trial programme designed to ascertain optimal dosing.
